Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]
Discontinued
Reference number: GID-TA10617
Following on from information provided to NICE by the company in May 2021, the appraisal of Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.